Luigi Muratori

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6582041/publications.pdf

Version: 2024-02-01

36303 69250 6,997 160 51 77 citations h-index g-index papers 162 162 162 3850 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nature Genetics, 2010, 42, 658-660.	21.4	389
2	Serum autoantibodies in chronic hepatitis C: Comparison with autoimmune hepatitis and impact on the disease profile. Hepatology, 1997, 26, 561-566.	7.3	225
3	Cytochrome P4502D6193–212: A New Immunodominant Epitope and Target of Virus/Self Cross-Reactivity in Liver Kidney Microsomal Autoantibody Type 1-Positive Liver Disease. Journal of Immunology, 2003, 170, 1481-1489.	0.8	196
4	Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. American Journal of Gastroenterology, 2003, 98, 431-437.	0.4	188
5	A multifaceted imbalance of T cells with regulatory function characterizes type 1 autoimmune hepatitis. Hepatology, 2010, 52, 999-1007.	7.3	175
6	Frequency and significance of anti-gliadin and anti-endomysial antibodies in autoimmune hepatitis. Digestive Diseases and Sciences, 1998, 43, 2190-2195.	2.3	158
7	Review article: autoimmune hepatitis - current management and challenges. Alimentary Pharmacology and Therapeutics, 2013, 38, 887-913.	3.7	146
8	Prevalence of non-organ-specific autoantibodies and chronic liver disease in the general population: a nested case-control study of the Dionysos cohort. Gut, 1999, 45, 435-441.	12.1	145
9	Celiac disease in autoimmune cholestatic liver disorders. American Journal of Gastroenterology, 2002, 97, 2609-2613.	0.4	136
10	Autoimmune hepatitis in Italy: The Bologna experience. Journal of Hepatology, 2009, 50, 1210-1218.	3.7	133
11	Anti-neutrophil cytoplasmic antibodies in type 1 and 2 autoimmune hepatitis. Hepatology, $1997, 25, 1105-1107$.	7.3	125
12	Human leukocyte antigen polymorphisms in italian primary biliary cirrhosis: A multicenter study of 664 patients and 1992 healthy controls. Hepatology, 2008, 48, 1906-1912.	7.3	120
13	The Serological Profile of the Autoimmune Hepatitis/Primary Biliary Cirrhosis Overlap Syndrome. American Journal of Gastroenterology, 2009, 104, 1420-1425.	0.4	111
14	Liver/kidney microsomal antibody type 1 and liver cytosol antibody type 1 concentrations in type 2 autoimmune hepatitis. Gut, 1998 , 42 , 721 - 726 .	12.1	109
15	Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score. The Lancet Gastroenterology and Hepatology, 2018, 3, 626-634.	8.1	103
16	Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment. World Journal of Gastroenterology, 2021, 27, 2994-3009.	3.3	103
17	Autoimmune hepatitis/primary biliary cirrhosis overlap syndrome and associated extrahepatic autoimmune diseases. European Journal of Gastroenterology and Hepatology, 2012, 24, 531-534.	1.6	100
18	Interferon therapy in liver/kidney microsomal antibody type 1-positive patients with chronic hepatitis C. Journal of Hepatology, 1994, 21, 199-203.	3.7	99

#	Article	IF	Citations
19	Liver/kidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane. Gut, 2000, 46, 553-561.	12.1	96
20	Non-organ specific autoantibodies in children with chronic hepatitis C. Journal of Hepatology, 1996, 25, 614-620.	3.7	85
21	Anti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseases. Clinical and Experimental Immunology, 2003, 132, 473-476.	2.6	84
22	Antibodies to filamentous actin (F-actin) in type 1 autoimmune hepatitis. Journal of Clinical Pathology, 2006, 59, 280-284.	2.0	83
23	Haplotype HLA-B8-DR3 Confers Susceptibility to Hepatitis C Virus-Related Mixed Cryoglobulinemia. Blood, 1998, 91, 2062-2066.	1.4	82
24	Multiple Viral/Self Immunological Cross-Reactivity in Liver Kidney Microsomal Antibody Positive Hepatitis C Virus-Infected Patients is Associated with the Possession of HLA B51. International Journal of Immunopathology and Pharmacology, 2004, 17, 83-92.	2.1	81
25	Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis. Liver International, 2004, 24, 322-329.	3.9	80
26	'True' antimitochondrial antibody-negative primary biliary cirrhosis, low sensitivity of the routine assays, or both?. Clinical and Experimental Immunology, 2004, 135, 154-158.	2.6	79
27	Type 1 autoimmune hepatitis: patterns of clinical presentation and differential diagnosis of the 'acute' type. QJM - Monthly Journal of the Association of Physicians, 2004, 97, 407-412.	0.5	79
28	Liver cytosolic 1 antigen-antibody system in type 2 autoimmune hepatitis and hepatitis C virus infection Gut, 1995, 36, 749-754.	12.1	77
29	Antibodies to SSâ€A/Roâ€52kD and centromere in autoimmune liver disease: a clue to diagnosis and prognosis of primary biliary cirrhosis. Alimentary Pharmacology and Therapeutics, 2007, 26, 831-838.	3.7	77
30	Heterogeneity of liver/kidney microsomal antibody type 1 in autoimmune hepatitis and hepatitis C virus related liver disease Gut, 1995 , 37 , $406-412$.	12.1	75
31	Key Residues of a Major Cytochrome P4502D6 Epitope Are Located on the Surface of the Molecule. Journal of Immunology, 2002, 169, 277-285.	0.8	74
32	Antinuclear antibodies as ancillary markers in primary biliary cirrhosis. Expert Review of Molecular Diagnostics, 2012, 12, 65-74.	3.1	74
33	Quantification of hepatitis C virus-infected peripheral blood mononuclear cells by in situ reverse transcriptase-polymerase chain reaction. Blood, 1996, 88, 2768-2774.	1.4	73
34	Antimitochondrial Antibodies and Other Antibodies in Primary Biliary Cirrhosis: Diagnostic and Prognostic Value. Clinics in Liver Disease, 2008, 12, 261-276.	2.1	72
35	Genetic distinctions between autoimmune hepatitis in Italy and North America. World Journal of Gastroenterology, 2005, 11, 1862.	3.3	70
36	PML Nuclear Body Component Sp140 Is a Novel Autoantigen in Primary Biliary Cirrhosis. American Journal of Gastroenterology, 2010, 105, 125-131.	0.4	69

3

#	Article	IF	CITATIONS
37	Antinuclear antibodies giving the 'multiple nuclear dots' or the 'rim-like/membranous' patterns: diagnostic accuracy for primary biliary cirrhosis. Alimentary Pharmacology and Therapeutics, 2006, 24, 1575-1583.	3.7	65
38	HCV and Autoimmunity. Current Pharmaceutical Design, 2008, 14, 1678-1685.	1.9	64
39	Factors Associated With Response to Therapy and Outcome ofÂPatients With Primary Biliary Cirrhosis With Features ofÂAutoimmune Hepatitis. Clinical Gastroenterology and Hepatology, 2014, 12, 863-869.	4.4	64
40	Smooth Muscle Antibodies and Type 1 Autoimmune Hepatitis. Autoimmunity, 2002, 35, 497-500.	2.6	63
41	An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs. Journal of Hepatology, 2021, 75, 572-581.	3.7	62
42	Clinical features of type 1 autoimmune hepatitis in elderly Italian patients. Alimentary Pharmacology and Therapeutics, 2005, 21, 1273-1277.	3.7	60
43	Autoimmune liver disease and concomitant extrahepatic autoimmune disease. European Journal of Gastroenterology and Hepatology, 2015, 27, 1175-1179.	1.6	60
44	Distinct epitopes on formiminotransferase cyclodeaminase induce autoimmune liver cytosol antibody type 1. Hepatology, 2001, 34, 494-501.	7.3	59
45	Application of the 2010 American Association for the study of liver diseases criteria of remission to a cohort of Italian patients with autoimmune hepatitis. Hepatology, 2010, 52, 1857-1857.	7.3	59
46	Anti-actin IgA antibodies in severe coeliac disease. Clinical and Experimental Immunology, 2004, 137, 386-392.	2.6	58
47	Validation of simplified diagnostic criteria for autoimmune hepatitis in Italian patients. Hepatology, 2009, 49, 1782-1783.	7.3	58
48	Clinical Impact of Non-Organ-Specific Autoantibodies on the Response to Combined Antiviral Treatment in Patients with Hepatitis C. Clinical Infectious Diseases, 2005, 40, 501-507.	5.8	57
49	Susceptibility to Thyroid Disorders in Hepatitis C. Clinical Gastroenterology and Hepatology, 2005, 3, 595-603.	4.4	57
50	Fatigue and pruritus at onset identify a more aggressive subset of primary biliary cirrhosis. Liver International, 2015, 35, 636-641.	3.9	57
51	Hepatitis C virus infection associated with liver-kidney microsomal antibody type 1 (LKM1) autoantibodies in children. Journal of Pediatrics, 2003, 142, 185-190.	1.8	54
52	Non-Organ-Specific Autoantibodies in Children with Chronic Hepatitis C: Clinical Significance and Impact on Interferon Treatment. Clinical Infectious Diseases, 2003, 37, 1320-1326.	5.8	53
53	Detection of anti-liver cytosol antibody type 1 (anti-LC1) by immunodiffusion, counterimmunoelectrophoresis and immunoblotting: comparison of different techniques. Journal of Immunological Methods, 1995, 187, 259-264.	1.4	51
54	Anti-Saccharomyces cerevisiae and perinuclear anti-neutrophil cytoplasmic antibodies in coeliac disease before and after gluten-free diet. Alimentary Pharmacology and Therapeutics, 2005, 21, 881-887.	3.7	51

#	Article	IF	CITATIONS
55	Establishment of a novel radioligand assay using eukaryotically expressed cytchrome P4502D6 for the measurement of liver kidney microsomal type 1 antibdy in patients with autoimmune hepatitis and hepatitis C virus infection. Journal of Hepatology, 1997, 26, 1396-1402.	3.7	49
56	Anti-multiple nuclear dots (anti-MND) and anti-SP100 antibodies in hepatic and rheumatological disorders. Clinical and Experimental Immunology, 2002, 127, 172-175.	2.6	46
57	The Hepatitic/Cholestatic "Overlap" Syndrome: An Italian Experience. Autoimmunity, 2002, 35, 565-568.	2.6	44
58	Testing for hepatitis C virus sequences in peripheral blood mononuclear cells of patients with chronic hepatitis C in the absence of serum hepatitis C virus RNA. Liver, 1994, 14, 124-128.	0.1	43
59	Type 1 and type 2 autoimmune hepatitis in adults share the same clinical phenotype. Alimentary Pharmacology and Therapeutics, 2015, 41, 1281-1287.	3.7	43
60	Serum autoantibodies and the diagnosis of type-1 autoimmune hepatitis in Italy: a reappraisal at the light of hepatitis C virus infection Gut, 1992, 33, 1260-1263.	12.1	41
61	Autoantibody appearance in cytomegalovirus-infected liver transplant recipients: Correlation with antigenemia. Journal of Medical Virology, 2002, 66, 56-62.	5.0	41
62	Prevalence of non-organ specific autoantibodies in HCV-infected subjects in the general population. Clinical and Experimental Immunology, 2003, 131, 118-121.	2.6	41
63	The interplay between regulatory and effector T cells in autoimmune hepatitis: Implications for innovative treatment strategies. Journal of Autoimmunity, 2013, 46, 74-80.	6.5	39
64	Autoimmune liver disease serology in acute hepatitis E virus infection. Journal of Autoimmunity, 2018, 94, 1-6.	6.5	39
65	Identification of New Autoantigens by Protein Array Indicates a Role for IL4 Neutralization in Autoimmune Hepatitis. Molecular and Cellular Proteomics, 2012, 11, 1885-1897.	3.8	38
66	Sex Differences Associated with Primary Biliary Cirrhosis. Clinical and Developmental Immunology, 2012, 2012, 1-11.	3.3	37
67	Extrahepatic autoimmune diseases in primary biliary cholangitis: Prevalence and significance for clinical presentation and disease outcome. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 936-942.	2.8	37
68	Smoking as a risk factor for autoimmune liver disease: what we can learn from primary biliary cirrhosis. Annals of Hepatology, 2012, 11, 7-14.	1.5	36
69	Antibodies to soluble liver antigen in patients with various liver diseases: A multicentre study. Liver International, 2013, 33, 190-196.	3.9	36
70	Impact of International Autoimmune Hepatitis Group scoring system in definition of autoimmune hepatitis. Digestive Diseases and Sciences, 1996, 41, 166-171.	2.3	35
71	Diagnosis and Therapy of Autoimmune Hepatitis. Mini-Reviews in Medicinal Chemistry, 2009, 9, 847-860.	2.4	35
72	Analysis of the hepatitis C virus genome in patients with anti-LKM-1 autoantibodies. Journal of Hepatology, 1994, 21, 273-276.	3.7	33

#	Article	IF	Citations
73	Hyperferritinemia and hypergammaglobulinemia predict the treatment response to standard therapy in autoimmune hepatitis. PLoS ONE, 2017, 12, e0179074.	2.5	33
74	Real-world experience with obeticholic acid in patients with primary biliary cholangitis. JHEP Reports, 2021, 3, 100248.	4.9	33
75	Clinical features and effect of antiviral therapy on anti-liver/kidney microsomal antibody type 1 positive chronic hepatitis C. Journal of Hepatology, 2009, 50, 1093-1101.	3.7	31
76	Enhanced monocyte Th1 cytokine production in HCV-infected cryoglobulinemic patients. Journal of Hepatology, 2003, 38, 230-236.	3.7	27
77	Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis. Digestive Diseases and Sciences, 2018, 63, 1348-1354.	2.3	27
78	X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis. Gastroenterology, 2021, 160, 2483-2495.e26.	1.3	27
79	Evidence of a Genetic Basis for the Different Geographic Occurrences of Liver/Kidney Microsomal Antibody Type 1 in Hepatitis C. Digestive Diseases and Sciences, 2007, 52, 179-184.	2.3	26
80	Features and Progression of Asymptomatic Autoimmune Hepatitis in Italy. Clinical Gastroenterology and Hepatology, 2016, 14, 139-146.	4.4	26
81	Sequential presentation of primary biliary cirrhosis and autoimmune hepatitis. European Journal of Gastroenterology and Hepatology, 2014, 26, 532-537.	1.6	25
82	Low hepatitis C viremia levels in patients with anti-liver/kidney microsomal antibody type 1 positive chronic hepatitis. Journal of Hepatology, 1996, 25, 433-438.	3.7	23
83	Antilactoferrin antibodies in autoimmune liver disease. Clinical and Experimental Immunology, 2001, 124, 470-473.	2.6	23
84	Predictive factors of poor response to therapy in Autoimmune Hepatitis. Digestive and Liver Disease, 2016, 48, 1078-1081.	0.9	23
85	Primary Biliary Cholangitis: advances in management and treatment of the disease. Digestive and Liver Disease, 2017, 49, 841-846.	0.9	23
86	Antibodies to carbonic anhydrase in autoimmune cholangiopathy. Gastroenterology, 1997, 112, 1053-1054.	1.3	22
87	Serum autoantibodies in chronic hepatitis C: Comparison with autoimmune hepatitis and impact on the disease profile. Hepatology, 1997, 26, 561-566.	7.3	22
88	LKM1 appearance in a HLA-DR3+ patient with chronic hepatitis C during interferon treatment. Journal of Hepatology, 1993, 18, 259-260.	3.7	21
89	Antitransglutaminase Antibodies and Giardiasis. American Journal of Gastroenterology, 2004, 99, 2505-2506.	0.4	21
90	Hepatitis C and autoreactivity. Digestive and Liver Disease, 2007, 39, S22-S24.	0.9	21

#	Article	IF	CITATIONS
91	Clinical and prognostic implications of acute onset of Autoimmune Hepatitis: An Italian multicentre study. Digestive and Liver Disease, 2018, 50, 698-702.	0.9	21
92	Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA Adverse Event Reporting System. Multiple Sclerosis Journal, 2019, 25, 1633-1640.	3.0	21
93	Permanent immunosuppression in SLA/LPâ€positive autoimmune hepatitis is required although overall response and survival are similar. Liver International, 2020, 40, 368-376.	3.9	21
94	Specificity of antiâ€sp100 antibody for primary biliary cirrhosis. Scandinavian Journal of Gastroenterology, 2004, 39, 405-406.	1.5	20
95	Coronavirus disease associated immune thrombocytopenia: Causation or correlation?. Journal of Microbiology, Immunology and Infection, 2021, 54, 531-533.	3.1	20
96	Smoking as a risk factor for autoimmune liver disease: what we can learn from primary biliary cirrhosis. Annals of Hepatology, 2012, 11, 7-14.	1.5	20
97	Spontaneous remission of autoimmune hepatitis during pregnancy. Digestive and Liver Disease, 2002, 34, 608-609.	0.9	19
98	The Western immunoblotting pattern of anti-mitochondrial antibodies is independent of the clinical expression of primary biliary cirrhosis. Digestive and Liver Disease, 2005, 37, 108-112.	0.9	19
99	Current topics in autoimmune hepatitis. Digestive and Liver Disease, 2010, 42, 757-764.	0.9	19
100	Autoimmune liver disease 2007. Molecular Aspects of Medicine, 2008, 29, 96-102.	6.4	18
101	Antinuclear antibodies in COVID 19. Clinical and Translational Science, 2021, 14, 1627-1628.	3.1	18
102	<i>De novo</i> autoimmune hepatitis in liver transplant: State-of-the-art review. World Journal of Gastroenterology, 2016, 22, 2906.	3.3	18
103	Clinical implications of antimitochondrial antibody seropositivity in autoimmune hepatitis: a multicentre study. European Journal of Gastroenterology and Hepatology, 2017, 29, 777-780.	1.6	17
104	Anti-saccharomyces cerevisiae antibodies (ASCA) in coeliac disease. Gut, 2006, 55, 296.	12.1	17
105	Quantification of hepatitis C virus-infected peripheral blood mononuclear cells by in situ reverse transcriptase-polymerase chain reaction. Blood, 1996, 88, 2768-74.	1.4	17
106	Autoimmune liver serology before and after successful treatment of chronic hepatitis C by direct acting antiviral agents. Journal of Autoimmunity, 2019, 102, 89-95.	6.5	16
107	Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis. Hepatology, 2022, 75, 13-27.	7.3	16
108	LKM1-Positive Type 2 Autoimmune Hepatitis Following Allogenic Hematopoietic Stem-Cell Transplantation. American Journal of Gastroenterology, 2008, 103, 1313-1314.	0.4	15

#	Article	IF	CITATIONS
109	Clinical and serological profile of primary biliary cirrhosis in men. QJM - Monthly Journal of the Association of Physicians, 2007, 100, 534-535.	0.5	14
110	Multiple nuclear dots and rim-like/membranous IgG isotypes in primary biliary cirrhosis. Autoimmunity, 2009, 42, 224-227.	2.6	14
111	Diagnostic difficulties, therapeutic strategies, and performance of scoring systems in patients with autoimmune hepatitis and concurrent hepatitis B/C. Scandinavian Journal of Gastroenterology, 2013, 48, 504-508.	1.5	14
112	Limitation of the simplified scoring system for the diagnosis of autoimmune Hepatitis with acute onset. Liver International, 2021, 41, 529-534.	3.9	14
113	New autoantibodies and autoantigens in autoimmune hepatitis. Clinics in Liver Disease, 2002, 6, 785-797.	2.1	13
114	Acute Icteric Hepatitis Induced By a Short Course of Low-Dose Cyclophosphamide in a Patient with Lupus Nephritis. Digestive Diseases and Sciences, 2005, 50, 2364-2365.	2.3	12
115	Autoantibodies in Autoimmune Hepatitis. Digestive Diseases, 2015, 33, 65-69.	1.9	12
116	A novel assay for detecting antibodies to cytochrome P4502D6, the molecular target of liver kidney microsomal antibody type 1. Journal of Immunological Methods, 1999, 223, 227-235.	1.4	11
117	Hepatic steatosis in chronic hepatitis C: impact on response to anti-viral treatment with peg-interferon and ribavirin. Alimentary Pharmacology and Therapeutics, 2005, 22, 943-949.	3.7	11
118	Diagnostic approach to autoimmune hepatitis. Expert Review of Clinical Immunology, 2017, 13, 769-779.	3.0	11
119	Diagnostic role of anti-dsDNA antibodies: do not forget autoimmune hepatitis. Nature Reviews Rheumatology, 2021, 17, 244-244.	8.0	11
120	Novel biomarkers for primary biliary cholangitis to improve diagnosis and understand underlying regulatory mechanisms. Liver International, 2019, 39, 2124-2135.	3.9	10
121	Hepatitis C virus and autoimmunity. Hepatology, 2000, 31, 1380-1380.	7. 3	10
122	Clinical and serological profile of primary biliary cirrhosis in young and elderly patients. QJM - Monthly Journal of the Association of Physicians, 2008, 101, 505-506.	0.5	9
123	Two of Them Do It Better: Novel Serum Biomarkers Improve Autoimmune Hepatitis Diagnosis. PLoS ONE, 2015, 10, e0137927.	2.5	9
124	Editorial: gut microbiota profile in patients with autoimmune hepatitis—a clue for adjunctive probiotic therapy?. Alimentary Pharmacology and Therapeutics, 2020, 52, 392-394.	3.7	9
125	Acute-on-chronic liver failure: A complex clinical entity in patients with autoimmune hepatitis. Journal of Hepatology, 2021, 75, 1503-1505.	3.7	9
126	Redistribution of regulatory T-cells across the evolving stages of chronic hepatitis C. Digestive and Liver Disease, 2011, 43, 807-813.	0.9	8

#	Article	IF	CITATIONS
127	Autoantibodies to speckled protein family in primary biliary cholangitis. Allergy, Asthma and Clinical Immunology, 2021, 17, 35.	2.0	8
128	Anti-neutrophil cytoplasm antibodies (ANCA) in autoimmune diseases: A matter of laboratory technique and clinical setting. Autoimmunity Reviews, 2021, 20, 102787.	5.8	8
129	Clinical update on risks and efficacy of anti-SARS-CoV-2 vaccines in patients with autoimmune hepatitis and summary of reports on post-vaccination liver injury. Digestive and Liver Disease, 2022, 54, 722-726.	0.9	8
130	Serum Antibody Reactivity to Human Intracisternal A-Type Particle Retrovirus Proteins in Systemic Sclerosis Patients. Acta Dermato-Venereologica, 2004, 84, 177-180.	1.3	7
131	Decompensated Cirrhosis as Presentation of LKM1/LC1 Positive Type 2 Autoimmune Hepatitis in Adulthood. A Rare Clinical Entity of Difficult Management. Gastroenterology Insights, 2021, 12, 67-75.	1.2	6
132	A new route to apoptosis in hepatitis C virus infection. Journal of Hepatology, 2001, 35, 814-815.	3.7	5
133	Immunoglobulin GM and KM Allotypes and Prevalence of Anti-LKM1 Autoantibodies in Patients with Hepatitis C Virus Infection. Journal of Virology, 2006, 80, 5097-5099.	3.4	5
134	Antifilamentous Actin Antibodies by ELISA for the Diagnosis of Type 1 Autoimmune Hepatitis. American Journal of Gastroenterology, 2007, 102, 1131-1132.	0.4	4
135	Regulatory T cell defects in adult autoimmune hepatitis. Journal of Hepatology, 2012, 57, 1154-1155.	3.7	4
136	Antiâ€ribosomal P protein antibody: an autoreactivity devoid of prognostic value in patients with autoimmune hepatitis. Liver International, 2014, 34, 1446-1446.	3.9	4
137	A practical histological approach to the diagnosis of autoimmune hepatitis: experience of an Italian tertiary referral center. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 937-945.	2.8	4
138	Surrogate Markers for Antimitochondrial Antibody–Negative Primary Biliary Cholangitis. American Journal of Gastroenterology, 2021, 116, 215-217.	0.4	3
139	Autoantibodies in antimithocondrial antibodies negative primary biliary cholangitis. Clinics and Research in Hepatology and Gastroenterology, 2017, 41, e47.	1.5	2
140	861 A COMPLEX IMMUNOREGULATORY DEFICIENCY CHARACTERISES TYPE 1 AUTOIMMUNE HEPATITIS. Journal of Hepatology, 2008, 48, S323.	3.7	1
141	877 INCREASED REGULATORY POTENTIAL AND IMBALANCE OF THE VDELTA1/VDELTA2 RATIO IN PATIENTS WITH DIFFERENT MANIFESTATIONS OF HEPATITIS C. Journal of Hepatology, 2009, 50, S319.	3.7	1
142	489 CLINICAL IMPACT AND BEHAVIOUR OF SERUM AUTOANTIBODIES IN ADULT LIVER TRANSPLANTATION. Journal of Hepatology, 2010, 52, S197-S198.	3.7	1
143	698 IMPAIRED REGULATORY ABILITY AND PREDOMINANCE OF THE GAMMA-DELTA VDELTA1 SUBSET IN PATIENTS WITH HCV-RELATED TYPE 2 CRYOGLOBULINEMIA. Journal of Hepatology, 2010, 52, S271-S272.	3.7	1
144	Antimitochondrial antibodies positive autoimmune hepatitis with acute onset. Scandinavian Journal of Gastroenterology, 2017, 52, 920-921.	1.5	1

#	Article	IF	CITATIONS
145	Standardization of Autoantibody Testing in Autoimmune Hepatitis. Clinical Reviews in Allergy and Immunology, 2020, 58, 39-39.	6.5	1
146	Does the presence of non-organ specific autoantibodies (NOSA) correlate with disease activity in HCV infected patients?. Journal of Hepatology, 2000, 32, 218.	3.7	0
147	Clinical presentation of autoimmune hepatitis (AIH). Journal of Hepatology, 2002, 36, 262-263.	3.7	O
148	Biochemical and histological hepatic disease activity in cryoglobulinemic patients. Journal of Hepatology, 2003, 38, 157.	3.7	0
149	Response to Dr. Bogdanos. American Journal of Gastroenterology, 2004, 99, 765-765.	0.4	0
150	Diagnostic accuracy of anti-nuclear antibodies giving a multiple nuclear dots (MND) or a membranous (RL/M) pattern in primary biliary cirrhosis. Digestive and Liver Disease, 2006, 38, A75.	0.9	0
151	Natural course and incidence of non-organ specific autoantibodies (NOSA) and HCV infection in the general population: A nested case-control study of the dionysos cohort. Digestive and Liver Disease, 2006, 38, A78-A79.	0.9	0
152	Anti-extractable nuclear antigens (ENA) antibodies in primary biliary cirrhosis. Digestive and Liver Disease, 2006, 38, A80-A81.	0.9	0
153	[537] ANTI-LIVER KIDNEY MICROSOME TYPE ONE (ANTI-LKM1) POSITIVE HCV-RELATED CHRONIC LIVER DISEASE: PRESENTATION AND NATURAL HISTORY. Journal of Hepatology, 2007, 46, S204.	3.7	0
154	[664] DETECTION OF MND AND RL/M ANTI-NUCLEAR ANTIBODIES PATTERNS: A RELIABLE DIAGNOSTIC TOOL IN ANTI-MITOCHONDRIAL ANTIBODIES NEGATIVE PRIMARY BILIARY CIRRHOSISd. Journal of Hepatology, 2007, 46, S251-S252.	3.7	0
155	665 PML NUCLEAR BODY COMPONENT SP140 IS A NOVEL AUTOANTIGEN IN PRIMARY BILIARY CIRRHOSIS. Journal of Hepatology, 2009, 50, S244.	3.7	0
156	687 AN INCREASED T-CELL REGULATORY ACTIVITY IN CHRONIC HEPATITIS C CORRELATES WITH NORMAL TRANSAMINASES, BUT ALSO WITH ADVANCED LIVER DISEASE. Journal of Hepatology, 2010, 52, S267-S268.	3.7	0
157	Smooth Muscle Autoantibodies. , 2014, , 491-495.		0
158	Diagnosis of primary biliary cholangitis in a "teen―male patient. Clinics and Research in Hepatology and Gastroenterology, 2019, 43, e20-e21.	1.5	0
159	Acute liver injury and anorexia nervosa: a case report. Italian Journal of Medicine, 2019, 13, 128-131.	0.3	0
160	Steatosis in chronic hepatitis C. Gut, 2006, 55, 1047; author reply 1047-8.	12.1	0